Head to Head Survey: Sanuwave Health (NASDAQ:SNWV) and INLIF (NASDAQ:INLF)

Sanuwave Health (NASDAQ:SNWV) and INLIF (NASDAQ:INLF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Insider and Institutional Ownership

42.5% of Sanuwave Health shares are held by institutional investors. 14.9% of Sanuwave Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Sanuwave Health and INLIF’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sanuwave Health	26.64%	-141.56%	34.53%
INLIF	N/A	N/A	N/A

Valuation and Earnings

This table compares Sanuwave Health and INLIF”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanuwave Health	$44.05 million	3.34	$11.81 million	($0.16)	-106.94
INLIF	$18.41 million	4.68	-$5.45 million	N/A	N/A

Sanuwave Health has higher revenue and earnings than INLIF.

Risk and Volatility

Sanuwave Health has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, INLIF has a beta of 3.39, meaning that its share price is 239% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Sanuwave Health and INLIF, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanuwave Health	1	1	1	1	2.50
INLIF	1	0	0	0	1.00

Sanuwave Health presently has a consensus target price of $51.00, suggesting a potential upside of 198.07%. Given Sanuwave Health’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Sanuwave Health is more favorable than INLIF.

Summary

Sanuwave Health beats INLIF on 10 of the 13 factors compared between the two stocks.

About Sanuwave Health

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company’s lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body’s normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

About INLIF

INLIF Ltd. is a holding company, which engages in the development of injection molding machine-dedicated manipulator arms. Its products include: Three-axis robot, Five-axis robot and bull head type manipulator. The company was founded on January 4, 2023 and is headquartered in Quanzhou, China.